LymphedemaV1, PascalFrancis, Corpus, bibRecord, 000904

Decongestive lymphatic therapy for patients with cancer-related or primary lymphedema

Identifieur interne : 000904 ( PascalFrancis/Corpus ); précédent : 000903; suivant : 000905

Decongestive lymphatic therapy for patients with cancer-related or primary lymphedema

Auteurs : Andrzej Szuba ; John P. Cooke ; Shuja Yousuf ; Stanley G. Rockson

Source :

The American journal of medicine [ 0002-9343 ] ; 2000.

RBID : Pascal:00-0487514

Descripteurs français

Pascal (Inist)
- Lymphoedème, Primaire, Secondaire, Tumeur maligne, Complication, Drainage, Lymphatique, Kinésithérapie, Prospective, Efficacité traitement, Homme, Etude cohorte, Décongestionnant, Antioedémateux.

English descriptors

KwdEn :
- Cohort study, Complication, Drainage, Human, Kinesitherapy, Lymphatic, Lymphedema, Malignant tumor, Primary, Prospective, Secondary, Treatment efficiency.

Abstract

PURPOSE: A prospective evaluation was undertaken to assess the efficacy of intensive, short-term decongestive lymphatic therapy coupled with focused patient instruction in long-term self-care for the management of lymphedema. METHODS: The therapeutic responses of 79 patients with lymphedema were analyzed prospectively. Each patient received intensive, short-term decongestive lymphatic therapy, with quantification of the extent and durability of the clinical response. Decongestive lymphatic therapy was performed by therapists trained in these techniques. The mean (±SD) duration of therapy was 8 ± 3 days. Instruction in self-management techniques was incorporated into the therapeutic regimen by day 3 of the patient's treatment. The mean period of follow-up was 38 ± 52 days. Changes in the volume of the affected limb were assessed with a geometric approximation derived from serial measurements of circumference along the axis of the limb. RESULTS: The mean short-term reduction in limb volume was 44% ± 62% of the excess volume in the upper extremities and 42% ± 40% in the lower extremities. At follow-up, these results were adequately sustained: mean long-term excess volume reductions of 38% ± 56% (upper extremities) and 41% ± 27% (lower extremities) were observed. CONCLUSION: Decongestive lymphatic therapy, combined with long-term self-management, is efficacious in treating patients with lymphedema of the extremity.

Notice en format standard (ISO 2709)

Pour connaître la documentation sur le format Inist Standard.

A01	`01`	`1`		`@0 0002-9343`
A02	`01`			`@0 AJMEAZ`
A03		`1`		`@0 Am. j. med.`
A05				`@2 109`
A06				`@2 4`
A08	`01`	`1`	`ENG`	`@1 Decongestive lymphatic therapy for patients with cancer-related or primary lymphedema`
A11	`01`	`1`		`@1 SZUBA (Andrzej)`
A11	`02`	`1`		`@1 COOKE (John P.)`
A11	`03`	`1`		`@1 YOUSUF (Shuja)`
A11	`04`	`1`		`@1 ROCKSON (Stanley G.)`
A14	`01`			`@1 Stanford Lymphedema Center, Division of Cardiovascular Medicine, Stanford University School of Medicine @2 Stanford, California @3 USA @Z 1 aut. @Z 2 aut. @Z 3 aut. @Z 4 aut.`
A20				`@1 296-300`
A21				`@1 2000`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 4562 @5 354000091052980050`
A44				`@0 0000 @1 © 2000 INIST-CNRS. All rights reserved.`
A45				`@0 19 ref.`
A47	`01`	`1`		`@0 00-0487514`
A60				`@1 P`
A61				`@0 A`
A64	`01`	`1`		`@0 The American journal of medicine`
A66	`01`			`@0 USA`
C01	`01`		`ENG`	@0 PURPOSE: A prospective evaluation was undertaken to assess the efficacy of intensive, short-term decongestive lymphatic therapy coupled with focused patient instruction in long-term self-care for the management of lymphedema. METHODS: The therapeutic responses of 79 patients with lymphedema were analyzed prospectively. Each patient received intensive, short-term decongestive lymphatic therapy, with quantification of the extent and durability of the clinical response. Decongestive lymphatic therapy was performed by therapists trained in these techniques. The mean (±SD) duration of therapy was 8 ± 3 days. Instruction in self-management techniques was incorporated into the therapeutic regimen by day 3 of the patient's treatment. The mean period of follow-up was 38 ± 52 days. Changes in the volume of the affected limb were assessed with a geometric approximation derived from serial measurements of circumference along the axis of the limb. RESULTS: The mean short-term reduction in limb volume was 44% ± 62% of the excess volume in the upper extremities and 42% ± 40% in the lower extremities. At follow-up, these results were adequately sustained: mean long-term excess volume reductions of 38% ± 56% (upper extremities) and 41% ± 27% (lower extremities) were observed. CONCLUSION: Decongestive lymphatic therapy, combined with long-term self-management, is efficacious in treating patients with lymphedema of the extremity.
C02	`01`	`X`		`@0 002B26O`
C03	`01`	`X`	`FRE`	`@0 Lymphoedème @5 01`
C03	`01`	`X`	`ENG`	`@0 Lymphedema @5 01`
C03	`01`	`X`	`SPA`	`@0 Linfedema @5 01`
C03	`02`	`X`	`FRE`	`@0 Primaire @5 02`
C03	`02`	`X`	`ENG`	`@0 Primary @5 02`
C03	`02`	`X`	`SPA`	`@0 Primario @5 02`
C03	`03`	`X`	`FRE`	`@0 Secondaire @5 03`
C03	`03`	`X`	`ENG`	`@0 Secondary @5 03`
C03	`03`	`X`	`SPA`	`@0 Secundario @5 03`
C03	`04`	`X`	`FRE`	`@0 Tumeur maligne @5 04`
C03	`04`	`X`	`ENG`	`@0 Malignant tumor @5 04`
C03	`04`	`X`	`SPA`	`@0 Tumor maligno @5 04`
C03	`05`	`X`	`FRE`	`@0 Complication @5 05`
C03	`05`	`X`	`ENG`	`@0 Complication @5 05`
C03	`05`	`X`	`SPA`	`@0 Complicación @5 05`
C03	`06`	`X`	`FRE`	`@0 Drainage @5 07`
C03	`06`	`X`	`ENG`	`@0 Drainage @5 07`
C03	`06`	`X`	`SPA`	`@0 Drenaje @5 07`
C03	`07`	`X`	`FRE`	`@0 Lymphatique @5 08`
C03	`07`	`X`	`ENG`	`@0 Lymphatic @5 08`
C03	`07`	`X`	`SPA`	`@0 Linfático @5 08`
C03	`08`	`X`	`FRE`	`@0 Kinésithérapie @5 10`
C03	`08`	`X`	`ENG`	`@0 Kinesitherapy @5 10`
C03	`08`	`X`	`SPA`	`@0 Quinesiterapia @5 10`
C03	`09`	`X`	`FRE`	`@0 Prospective @5 17`
C03	`09`	`X`	`ENG`	`@0 Prospective @5 17`
C03	`09`	`X`	`SPA`	`@0 Prospectiva @5 17`
C03	`10`	`X`	`FRE`	`@0 Efficacité traitement @5 18`
C03	`10`	`X`	`ENG`	`@0 Treatment efficiency @5 18`
C03	`10`	`X`	`SPA`	`@0 Eficacia tratamiento @5 18`
C03	`11`	`X`	`FRE`	`@0 Homme @5 20`
C03	`11`	`X`	`ENG`	`@0 Human @5 20`
C03	`11`	`X`	`SPA`	`@0 Hombre @5 20`
C03	`12`	`X`	`FRE`	`@0 Etude cohorte @5 21`
C03	`12`	`X`	`ENG`	`@0 Cohort study @5 21`
C03	`12`	`X`	`SPA`	`@0 Estudio cohorte @5 21`
C03	`13`	`X`	`FRE`	`@0 Décongestionnant @4 INC @5 86`
C03	`14`	`X`	`FRE`	`@0 Antioedémateux @4 INC @5 87`
C07	`01`	`X`	`FRE`	`@0 Appareil circulatoire pathologie @5 37`
C07	`01`	`X`	`ENG`	`@0 Cardiovascular disease @5 37`
C07	`01`	`X`	`SPA`	`@0 Aparato circulatorio patología @5 37`
C07	`02`	`X`	`FRE`	`@0 Lymphatique pathologie @5 38`
C07	`02`	`X`	`ENG`	`@0 Lymphatic vessel disease @5 38`
C07	`02`	`X`	`SPA`	`@0 Linfático patología @5 38`
C07	`03`	`X`	`FRE`	`@0 Réadaptation physique @5 61`
C07	`03`	`X`	`ENG`	`@0 Physical rehabilitation @5 61`
C07	`03`	`X`	`SPA`	`@0 Readaptación física @5 61`
N21				`@1 325`

Format Inist (serveur)

NO :	PASCAL 00-0487514 INIST
ET :	Decongestive lymphatic therapy for patients with cancer-related or primary lymphedema
AU :	SZUBA (Andrzej); COOKE (John P.); YOUSUF (Shuja); ROCKSON (Stanley G.)
AF :	Stanford Lymphedema Center, Division of Cardiovascular Medicine, Stanford University School of Medicine/Stanford, California/Etats-Unis (1 aut., 2 aut., 3 aut., 4 aut.)
DT :	Publication en série; Niveau analytique
SO :	The American journal of medicine; ISSN 0002-9343; Coden AJMEAZ; Etats-Unis; Da. 2000; Vol. 109; No. 4; Pp. 296-300; Bibl. 19 ref.
LA :	Anglais
EA :	PURPOSE: A prospective evaluation was undertaken to assess the efficacy of intensive, short-term decongestive lymphatic therapy coupled with focused patient instruction in long-term self-care for the management of lymphedema. METHODS: The therapeutic responses of 79 patients with lymphedema were analyzed prospectively. Each patient received intensive, short-term decongestive lymphatic therapy, with quantification of the extent and durability of the clinical response. Decongestive lymphatic therapy was performed by therapists trained in these techniques. The mean (±SD) duration of therapy was 8 ± 3 days. Instruction in self-management techniques was incorporated into the therapeutic regimen by day 3 of the patient's treatment. The mean period of follow-up was 38 ± 52 days. Changes in the volume of the affected limb were assessed with a geometric approximation derived from serial measurements of circumference along the axis of the limb. RESULTS: The mean short-term reduction in limb volume was 44% ± 62% of the excess volume in the upper extremities and 42% ± 40% in the lower extremities. At follow-up, these results were adequately sustained: mean long-term excess volume reductions of 38% ± 56% (upper extremities) and 41% ± 27% (lower extremities) were observed. CONCLUSION: Decongestive lymphatic therapy, combined with long-term self-management, is efficacious in treating patients with lymphedema of the extremity.
CC :	002B26O
FD :	Lymphoedème; Primaire; Secondaire; Tumeur maligne; Complication; Drainage; Lymphatique; Kinésithérapie; Prospective; Efficacité traitement; Homme; Etude cohorte; Décongestionnant; Antioedémateux
FG :	Appareil circulatoire pathologie; Lymphatique pathologie; Réadaptation physique
ED :	Lymphedema; Primary; Secondary; Malignant tumor; Complication; Drainage; Lymphatic; Kinesitherapy; Prospective; Treatment efficiency; Human; Cohort study
EG :	Cardiovascular disease; Lymphatic vessel disease; Physical rehabilitation
SD :	Linfedema; Primario; Secundario; Tumor maligno; Complicación; Drenaje; Linfático; Quinesiterapia; Prospectiva; Eficacia tratamiento; Hombre; Estudio cohorte
LO :	INIST-4562.354000091052980050
ID :	00-0487514

Links to Exploration step

Pascal:00-0487514

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Decongestive lymphatic therapy for patients with cancer-related or primary lymphedema</title>
<author><name sortKey="Szuba, Andrzej" sort="Szuba, Andrzej" uniqKey="Szuba A" first="Andrzej" last="Szuba">Andrzej Szuba</name>
<affiliation><inist:fA14 i1="01"><s1>Stanford Lymphedema Center, Division of Cardiovascular Medicine, Stanford University School of Medicine</s1>
<s2>Stanford, California</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Cooke, John P" sort="Cooke, John P" uniqKey="Cooke J" first="John P." last="Cooke">John P. Cooke</name>
<affiliation><inist:fA14 i1="01"><s1>Stanford Lymphedema Center, Division of Cardiovascular Medicine, Stanford University School of Medicine</s1>
<s2>Stanford, California</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Yousuf, Shuja" sort="Yousuf, Shuja" uniqKey="Yousuf S" first="Shuja" last="Yousuf">Shuja Yousuf</name>
<affiliation><inist:fA14 i1="01"><s1>Stanford Lymphedema Center, Division of Cardiovascular Medicine, Stanford University School of Medicine</s1>
<s2>Stanford, California</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Rockson, Stanley G" sort="Rockson, Stanley G" uniqKey="Rockson S" first="Stanley G." last="Rockson">Stanley G. Rockson</name>
<affiliation><inist:fA14 i1="01"><s1>Stanford Lymphedema Center, Division of Cardiovascular Medicine, Stanford University School of Medicine</s1>
<s2>Stanford, California</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">00-0487514</idno>
<date when="2000">2000</date>
<idno type="stanalyst">PASCAL 00-0487514 INIST</idno>
<idno type="RBID">Pascal:00-0487514</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000904</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Decongestive lymphatic therapy for patients with cancer-related or primary lymphedema</title>
<author><name sortKey="Szuba, Andrzej" sort="Szuba, Andrzej" uniqKey="Szuba A" first="Andrzej" last="Szuba">Andrzej Szuba</name>
<affiliation><inist:fA14 i1="01"><s1>Stanford Lymphedema Center, Division of Cardiovascular Medicine, Stanford University School of Medicine</s1>
<s2>Stanford, California</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Cooke, John P" sort="Cooke, John P" uniqKey="Cooke J" first="John P." last="Cooke">John P. Cooke</name>
<affiliation><inist:fA14 i1="01"><s1>Stanford Lymphedema Center, Division of Cardiovascular Medicine, Stanford University School of Medicine</s1>
<s2>Stanford, California</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Yousuf, Shuja" sort="Yousuf, Shuja" uniqKey="Yousuf S" first="Shuja" last="Yousuf">Shuja Yousuf</name>
<affiliation><inist:fA14 i1="01"><s1>Stanford Lymphedema Center, Division of Cardiovascular Medicine, Stanford University School of Medicine</s1>
<s2>Stanford, California</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Rockson, Stanley G" sort="Rockson, Stanley G" uniqKey="Rockson S" first="Stanley G." last="Rockson">Stanley G. Rockson</name>
<affiliation><inist:fA14 i1="01"><s1>Stanford Lymphedema Center, Division of Cardiovascular Medicine, Stanford University School of Medicine</s1>
<s2>Stanford, California</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">The American journal of medicine</title>
<title level="j" type="abbreviated">Am. j. med.</title>
<idno type="ISSN">0002-9343</idno>
<imprint><date when="2000">2000</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">The American journal of medicine</title>
<title level="j" type="abbreviated">Am. j. med.</title>
<idno type="ISSN">0002-9343</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Cohort study</term>
<term>Complication</term>
<term>Drainage</term>
<term>Human</term>
<term>Kinesitherapy</term>
<term>Lymphatic</term>
<term>Lymphedema</term>
<term>Malignant tumor</term>
<term>Primary</term>
<term>Prospective</term>
<term>Secondary</term>
<term>Treatment efficiency</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Lymphoedème</term>
<term>Primaire</term>
<term>Secondaire</term>
<term>Tumeur maligne</term>
<term>Complication</term>
<term>Drainage</term>
<term>Lymphatique</term>
<term>Kinésithérapie</term>
<term>Prospective</term>
<term>Efficacité traitement</term>
<term>Homme</term>
<term>Etude cohorte</term>
<term>Décongestionnant</term>
<term>Antioedémateux</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">PURPOSE: A prospective evaluation was undertaken to assess the efficacy of intensive, short-term decongestive lymphatic therapy coupled with focused patient instruction in long-term self-care for the management of lymphedema. METHODS: The therapeutic responses of 79 patients with lymphedema were analyzed prospectively. Each patient received intensive, short-term decongestive lymphatic therapy, with quantification of the extent and durability of the clinical response. Decongestive lymphatic therapy was performed by therapists trained in these techniques. The mean (±SD) duration of therapy was 8 ± 3 days. Instruction in self-management techniques was incorporated into the therapeutic regimen by day 3 of the patient's treatment. The mean period of follow-up was 38 ± 52 days. Changes in the volume of the affected limb were assessed with a geometric approximation derived from serial measurements of circumference along the axis of the limb. RESULTS: The mean short-term reduction in limb volume was 44% ± 62% of the excess volume in the upper extremities and 42% ± 40% in the lower extremities. At follow-up, these results were adequately sustained: mean long-term excess volume reductions of 38% ± 56% (upper extremities) and 41% ± 27% (lower extremities) were observed. CONCLUSION: Decongestive lymphatic therapy, combined with long-term self-management, is efficacious in treating patients with lymphedema of the extremity.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0002-9343</s0>
</fA01>
<fA02 i1="01"><s0>AJMEAZ</s0>
</fA02>
<fA03 i2="1"><s0>Am. j. med.</s0>
</fA03>
<fA05><s2>109</s2>
</fA05>
<fA06><s2>4</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Decongestive lymphatic therapy for patients with cancer-related or primary lymphedema</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>SZUBA (Andrzej)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>COOKE (John P.)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>YOUSUF (Shuja)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>ROCKSON (Stanley G.)</s1>
</fA11>
<fA14 i1="01"><s1>Stanford Lymphedema Center, Division of Cardiovascular Medicine, Stanford University School of Medicine</s1>
<s2>Stanford, California</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</fA14>
<fA20><s1>296-300</s1>
</fA20>
<fA21><s1>2000</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>4562</s2>
<s5>354000091052980050</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2000 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>19 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>00-0487514</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>The American journal of medicine</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>PURPOSE: A prospective evaluation was undertaken to assess the efficacy of intensive, short-term decongestive lymphatic therapy coupled with focused patient instruction in long-term self-care for the management of lymphedema. METHODS: The therapeutic responses of 79 patients with lymphedema were analyzed prospectively. Each patient received intensive, short-term decongestive lymphatic therapy, with quantification of the extent and durability of the clinical response. Decongestive lymphatic therapy was performed by therapists trained in these techniques. The mean (±SD) duration of therapy was 8 ± 3 days. Instruction in self-management techniques was incorporated into the therapeutic regimen by day 3 of the patient's treatment. The mean period of follow-up was 38 ± 52 days. Changes in the volume of the affected limb were assessed with a geometric approximation derived from serial measurements of circumference along the axis of the limb. RESULTS: The mean short-term reduction in limb volume was 44% ± 62% of the excess volume in the upper extremities and 42% ± 40% in the lower extremities. At follow-up, these results were adequately sustained: mean long-term excess volume reductions of 38% ± 56% (upper extremities) and 41% ± 27% (lower extremities) were observed. CONCLUSION: Decongestive lymphatic therapy, combined with long-term self-management, is efficacious in treating patients with lymphedema of the extremity.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B26O</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Lymphoedème</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Lymphedema</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Linfedema</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Primaire</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Primary</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Primario</s0>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Secondaire</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Secondary</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Secundario</s0>
<s5>03</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Tumeur maligne</s0>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Malignant tumor</s0>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Tumor maligno</s0>
<s5>04</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Complication</s0>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Complication</s0>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Complicación</s0>
<s5>05</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Drainage</s0>
<s5>07</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Drainage</s0>
<s5>07</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Drenaje</s0>
<s5>07</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Lymphatique</s0>
<s5>08</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Lymphatic</s0>
<s5>08</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Linfático</s0>
<s5>08</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE"><s0>Kinésithérapie</s0>
<s5>10</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG"><s0>Kinesitherapy</s0>
<s5>10</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA"><s0>Quinesiterapia</s0>
<s5>10</s5>
</fC03>
<fC03 i1="09" i2="X" l="FRE"><s0>Prospective</s0>
<s5>17</s5>
</fC03>
<fC03 i1="09" i2="X" l="ENG"><s0>Prospective</s0>
<s5>17</s5>
</fC03>
<fC03 i1="09" i2="X" l="SPA"><s0>Prospectiva</s0>
<s5>17</s5>
</fC03>
<fC03 i1="10" i2="X" l="FRE"><s0>Efficacité traitement</s0>
<s5>18</s5>
</fC03>
<fC03 i1="10" i2="X" l="ENG"><s0>Treatment efficiency</s0>
<s5>18</s5>
</fC03>
<fC03 i1="10" i2="X" l="SPA"><s0>Eficacia tratamiento</s0>
<s5>18</s5>
</fC03>
<fC03 i1="11" i2="X" l="FRE"><s0>Homme</s0>
<s5>20</s5>
</fC03>
<fC03 i1="11" i2="X" l="ENG"><s0>Human</s0>
<s5>20</s5>
</fC03>
<fC03 i1="11" i2="X" l="SPA"><s0>Hombre</s0>
<s5>20</s5>
</fC03>
<fC03 i1="12" i2="X" l="FRE"><s0>Etude cohorte</s0>
<s5>21</s5>
</fC03>
<fC03 i1="12" i2="X" l="ENG"><s0>Cohort study</s0>
<s5>21</s5>
</fC03>
<fC03 i1="12" i2="X" l="SPA"><s0>Estudio cohorte</s0>
<s5>21</s5>
</fC03>
<fC03 i1="13" i2="X" l="FRE"><s0>Décongestionnant</s0>
<s4>INC</s4>
<s5>86</s5>
</fC03>
<fC03 i1="14" i2="X" l="FRE"><s0>Antioedémateux</s0>
<s4>INC</s4>
<s5>87</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Appareil circulatoire pathologie</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Cardiovascular disease</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Aparato circulatorio patología</s0>
<s5>37</s5>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Lymphatique pathologie</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Lymphatic vessel disease</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Linfático patología</s0>
<s5>38</s5>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Réadaptation physique</s0>
<s5>61</s5>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Physical rehabilitation</s0>
<s5>61</s5>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Readaptación física</s0>
<s5>61</s5>
</fC07>
<fN21><s1>325</s1>
</fN21>
</pA>
</standard>
<server><NO>PASCAL 00-0487514 INIST</NO>
<ET>Decongestive lymphatic therapy for patients with cancer-related or primary lymphedema</ET>
<AU>SZUBA (Andrzej); COOKE (John P.); YOUSUF (Shuja); ROCKSON (Stanley G.)</AU>
<AF>Stanford Lymphedema Center, Division of Cardiovascular Medicine, Stanford University School of Medicine/Stanford, California/Etats-Unis (1 aut., 2 aut., 3 aut., 4 aut.)</AF>
<DT>Publication en série; Niveau analytique</DT>
<SO>The American journal of medicine; ISSN 0002-9343; Coden AJMEAZ; Etats-Unis; Da. 2000; Vol. 109; No. 4; Pp. 296-300; Bibl. 19 ref.</SO>
<LA>Anglais</LA>
<EA>PURPOSE: A prospective evaluation was undertaken to assess the efficacy of intensive, short-term decongestive lymphatic therapy coupled with focused patient instruction in long-term self-care for the management of lymphedema. METHODS: The therapeutic responses of 79 patients with lymphedema were analyzed prospectively. Each patient received intensive, short-term decongestive lymphatic therapy, with quantification of the extent and durability of the clinical response. Decongestive lymphatic therapy was performed by therapists trained in these techniques. The mean (±SD) duration of therapy was 8 ± 3 days. Instruction in self-management techniques was incorporated into the therapeutic regimen by day 3 of the patient's treatment. The mean period of follow-up was 38 ± 52 days. Changes in the volume of the affected limb were assessed with a geometric approximation derived from serial measurements of circumference along the axis of the limb. RESULTS: The mean short-term reduction in limb volume was 44% ± 62% of the excess volume in the upper extremities and 42% ± 40% in the lower extremities. At follow-up, these results were adequately sustained: mean long-term excess volume reductions of 38% ± 56% (upper extremities) and 41% ± 27% (lower extremities) were observed. CONCLUSION: Decongestive lymphatic therapy, combined with long-term self-management, is efficacious in treating patients with lymphedema of the extremity.</EA>
<CC>002B26O</CC>
<FD>Lymphoedème; Primaire; Secondaire; Tumeur maligne; Complication; Drainage; Lymphatique; Kinésithérapie; Prospective; Efficacité traitement; Homme; Etude cohorte; Décongestionnant; Antioedémateux</FD>
<FG>Appareil circulatoire pathologie; Lymphatique pathologie; Réadaptation physique</FG>
<ED>Lymphedema; Primary; Secondary; Malignant tumor; Complication; Drainage; Lymphatic; Kinesitherapy; Prospective; Treatment efficiency; Human; Cohort study</ED>
<EG>Cardiovascular disease; Lymphatic vessel disease; Physical rehabilitation</EG>
<SD>Linfedema; Primario; Secundario; Tumor maligno; Complicación; Drenaje; Linfático; Quinesiterapia; Prospectiva; Eficacia tratamiento; Hombre; Estudio cohorte</SD>
<LO>INIST-4562.354000091052980050</LO>
<ID>00-0487514</ID>
</server>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/PascalFrancis/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000904 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 000904 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Sante
   |area=    LymphedemaV1
   |flux=    PascalFrancis
   |étape=   Corpus
   |type=    RBID
   |clé=     Pascal:00-0487514
   |texte=   Decongestive lymphatic therapy for patients with cancer-related or primary lymphedema
}}

This area was generated with Dilib version V0.6.31.
Data generation: Sat Nov 4 17:40:35 2017. Site generation: Tue Feb 13 16:42:16 2024

	Serveur d'exploration sur le lymphœdème
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur le lymphœdème

Decongestive lymphatic therapy for patients with cancer-related or primary lymphedema

Decongestive lymphatic therapy for patients with cancer-related or primary lymphedema

Source :

Descripteurs français

English descriptors

Abstract

Notice en format standard (ISO 2709)

Format Inist (serveur)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri